The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News and events

News and events

News

01/05/2018 Physiogenex to present its NASH hamster model at NASH-TAG 2018

Physiogenex will present at the NASH-TAG 2018 in Park City, UT, USA, January 4th-6th, 2018. Dr. François Briand, Director of Research and Business Development, will be presenting a poster about the effects of obeticholic acid and elafibranor in the Diet-Induced NASH (DIN) hamster model. Looking forward to meet you there! About Physiogenex Physiogenex is a leading […]

Read more

11/08/2017 Physiogenex to present its NASH models at EASL NAFLD Summit 2017

Physiogenex will present at the EASL NAFLD Summit in Rome, Italy, November 9th-11th, 2017. Dr. François Briand, Director of Research and Business Development, will be presenting an e-poster about the effects of obeticholic acid in various Physiogenex preclinical NASH models, during the e-poster session 3, Nov. the 9th, 08:00pm-08:20pm. If you wish to further discuss about […]

Read more

10/30/2017 Physiogenex and CLEA Japan Inc. to present at the Kidney Week 2017, Oct. 31st- Nov. 5th, 2017, New Orleans, LA, USA.

Dapagliflozin Alone or Combined with Ramipril Improves Hyperglycemia and Hypertension and Prevents Kidney Complications and GFR Decline in the Nephrectomized SDT Fatty Rat Model of Diabetic Nephropathy. Read the abstract Through their partnership put in place in January 2016, Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model […]

Read more

10/09/2017 Physiogenex will be at the AASLD Liver Meeting 2017

Physiogenex will be attending the AASLD Liver Meeting 2017 in Washington DC, October 20th-24th, 2017. If you wish to know more about our preclinical NASH models to optimize your preclinical drug development program, please contact us to set-up an appointment with Dr. François Briand, Director of Research and Business Development during the Liver meeting. We […]

Read more

06/10/2017 Physiogenex presents the effects of SGLT2 inhibition and glucagon on intestinal cholesterol absorption at ADA 2017, San Diego, USA

Physiogenex has investigated the acute effects of SGLT2 inhibition and glucagon on intestinal cholesterol absorption in the Golden Syrian hamster model. Dr. François Briand, Director of Research and Business Development at Physiogenex, will present the study results during the 77th American Diabetes Association 2017 scientific sessions in San Diego, CA, USA. The oral presentation is scheduled during the oral […]

Read more

06/04/2017 Physiogenex and CLEA Japan Inc. present the benefits of SGLT2 inhibitor dapagliflozin on their 10-week rat model for evaluating drugs targeting Diabetic Nephropathy at ERA-EDTA 2017 congress in Madrid, Spain

Through their partnership put in place in January 2016, Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model for evaluating drugs targeting Diabetic Nephropathy. The Spontaneously Diabetic Torii fatty (SDT fatty) rat, a model of obesity type 2 diabetes distributed by CLEA Japan Inc. since 2012, has been […]

Read more

05/19/2017 Physiogenex and CLEA Japan Inc. present the benefits of SGLT2 inhibitor dapagliflozin on their 10-week rat model for evaluating drugs targeting Diabetic Nephropathy at EDNSG 2017 in Helsinki

Through their partnership put in place in January 2016, Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model for evaluating drugs targeting Diabetic Nephropathy. The Spontaneously Diabetic Torii fatty (SDT fatty) rat, a model of obesity type 2 diabetes distributed by CLEA Japan Inc. since 2012, has been […]

Read more

04/04/2017 Physiogenex and CLEA Japan Inc. present the benefits of SGLT2 inhibitor dapagliflozin on their 10-week rat model for evaluating drugs targeting Diabetic Nephropathy at the World Congress of Nephrology in Mexico

Through their partnership put in place in January 2016, Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model for evaluating drugs targeting Diabetic Nephropathy. The Spontaneously Diabetic Torii fatty (SDT fatty) rat, a model of obesity type 2 diabetes distributed by CLEA Japan Inc. since 2012, has been […]

Read more

02/28/2017 Physiogenex will present the effects of obeticholic acid in its novel Diet-Induced NASH (DIN) hamster model at the Keystone Symposium on Bile Acid Receptors as Signal Integrators in Liver and Metabolism, in Monterey, CA, USA, March 3-7, 2017.

Unlike rats and mice, the DIN hamster has a closer lipid/lipoprotein metabolism as compared to humans. In fact, it replicates the LDL increase and HDL lowering induced by obeticholic acid, as observed in clinical trials. This unique model to evaluate drugs targeting NASH will be presented by Dr. François Briand, Director of Research and Business […]

Read more

Events

02/07/2017 Physiogenex to present its 3-week NASH screening mouse model and the Diet-Induced NASH hamster model at the APASL 2017 in Shanghai.

Physiogenex will present its 3-week NASH screening model and the Diet-Induced NASH (DIN) hamster model during the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), February 15-19, 2017 in Shanghai, China. These models will be presented by Dr. François Briand, Director of Research and Business Development at Physiogenex, during oral abstracts […]

Read more